Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant

Neurology

Volumn 79, Issue 23, 2012, Pages 2265-2274

  Herring, W Joseph ^a   Snyder, Ellen ^a   Budd, Kerry ^a   Hutzelmann, Jill ^a   Snavely, Duane ^a   Liu, Kenneth ^a   Lines, Christopher ^a   Roth, Thomas ^a,b   Michelson, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUVOREXANT;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HUMAN; INSOMNIA; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PARASOMNIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SLEEP INDUCTION; SLEEP QUALITY; SLEEP TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL HALLUCINATION;

EID: 84871323368     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827688ee     Document Type: Article

References (29)

1. Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry 1992;53(suppl):14-18.
2. Wafford K, Ebert B. Emerging anti-insomnia drugs: tackling sleepiness and the quality of wake time. Nat Rev Drug Discov 2008;7:530-540.
3. De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-327.
4. Hagan JJ, Leslie RA, Patel S, et al. Orexin activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999;14:10911-10916.
5. Kilduff TS, Peyron C. The hypocretin/orexin ligandreceptor system: implications for sleep and sleep disorders. Trends Neurosci 2000;23:359-365.
6. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8: 171-181.
7. Scammell TE, Saper CB. Orexins: looking forward to sleep, back at addiction. Nat Med 2007;13:126-128.
8. Ohno K, Sakurai T. Orexin neuronal circuitry: role in regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87.
9. Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8:977-987.
10. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-266.
11. Gerrard PA, Porter R, Holland V, et al. Preclinical pharmacology of SB-649868: a novel orexin OX1/OX2 receptor antagonist possessing potent hypnotic activity in rodents and primates. Sleep 2009;32(suppl):A42. Abstract.
12. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-155.
13. Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012;91:975-985.
14. Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-1233.
15. Bettica PU, Lichtenfeld U, Squassante L, et al. The orexin receptor antagonist SB-649868 promotes and maintains sleep in healthy volunteers and in patients with primary insomnia. Sleep 2009;32(suppl):A252. Abstract.
16. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan- 1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-5332.
17. Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by MK-4305: a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61.
18. Sun H, Kennedy W, Lewis N, et al. Dose effects of MK-4305, a dual orexin receptor antagonist for insomnia, in healthy male subjects. J Sleep Res 2010;19(suppl 2):199-200.
19. Sun H, Kennedy WD, Lewis N, et al. The single dose pharmacokinetic and pharmacodynamic profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects. Sleep Biol Rhythms 2011;9:332.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
21. Iber C, Ancoli-Israel S, Chesson A, Quan SF; for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, 1st ed. Westchester, IL: American Academy of Sleep Medicine; 2007.
22. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
23. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11:89-95.
24. Leon AC, OlfsonM, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93-105.
25. Wechsler D. WAIS-R Manual. New York: The Psychological Corporation; 1981.
26. Kaplan E, Fein D, Morris R, Delis D. WAIS-R as a Neuropsychological Instrument. San Antonio: The Psychological Corporation; 1991.
27. Tyrer P, Murphy S, Riley P. The benzodiazepine withdrawal symptom questionnaire. J Affect Disord 1990;19:53-56.
28. Lankford DA, Corser BC, Zheng YP, et al. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies. Sleep 2008;31:1359-1370.
29. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci 2006;27:368-374.